Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure

A. R.J. Girbes, C. J. Kalisvaart, D. J. Van Veldhuisen, E. T. Tan, A. J. Smit, W. D. Reitsma, W. H. Pasteuning

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The effects of a single dose of ibopamine on renal haemodynamics, sodium excretion, blood pressure (BP) and heart rate (HR) were investigated in 10 patients (aged 52-82 years) with severe congestive heart failure (CHF) who were in NYHA class IV. All patients used ACE inhibitors, digoxin and diuretics. After determining baseline values, ibopamine 100 mg was administered.Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured simultaneously using radio pharmaceuticals. An increase in GFR and ERPF was observed during 3 and 2 h, with a maximum of 15 and 11%, respectively. The ratio GFR/ERPF representing the filtration fraction (FF) was markedly elevated at baseline, 34%, and remained unchanged. No clinically significant increase of sodium excretion was found. No changes in blood pressure, heart rate, plasma renin activity (PRA) and aldosterone or norepinephrine were observed. We conclude that ibopamine increases both ERPF and GFR in patients with severe CHF, possibly as a consequence of both inotropic cardiac and specific renal effects with equal preglomerular and postglomerular vasodilation. The lack of the presumed fall in FF may be the consequence of the expected DA1-induced renal vasodilation, partially reversed by the alpha adrenergic properties of ibopamine for this dose. Ibopamine caused no clinically significant natriuresis in these salt-depleted patients. No changes in PRA, aldosterone and catecholamines were found.

Original languageEnglish
Pages (from-to)279-283
Number of pages5
JournalEuropean Heart Journal
Volume14
Issue number2
DOIs
Publication statusPublished - 1 Jan 1993

Cite this

Girbes, A. R. J., Kalisvaart, C. J., Van Veldhuisen, D. J., Tan, E. T., Smit, A. J., Reitsma, W. D., & Pasteuning, W. H. (1993). Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure. European Heart Journal, 14(2), 279-283. https://doi.org/10.1093/eurheartj/14.2.279
Girbes, A. R.J. ; Kalisvaart, C. J. ; Van Veldhuisen, D. J. ; Tan, E. T. ; Smit, A. J. ; Reitsma, W. D. ; Pasteuning, W. H. / Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure. In: European Heart Journal. 1993 ; Vol. 14, No. 2. pp. 279-283.
@article{c6e152acd02d4c4fba620cc1ef92a65e,
title = "Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure",
abstract = "The effects of a single dose of ibopamine on renal haemodynamics, sodium excretion, blood pressure (BP) and heart rate (HR) were investigated in 10 patients (aged 52-82 years) with severe congestive heart failure (CHF) who were in NYHA class IV. All patients used ACE inhibitors, digoxin and diuretics. After determining baseline values, ibopamine 100 mg was administered.Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured simultaneously using radio pharmaceuticals. An increase in GFR and ERPF was observed during 3 and 2 h, with a maximum of 15 and 11{\%}, respectively. The ratio GFR/ERPF representing the filtration fraction (FF) was markedly elevated at baseline, 34{\%}, and remained unchanged. No clinically significant increase of sodium excretion was found. No changes in blood pressure, heart rate, plasma renin activity (PRA) and aldosterone or norepinephrine were observed. We conclude that ibopamine increases both ERPF and GFR in patients with severe CHF, possibly as a consequence of both inotropic cardiac and specific renal effects with equal preglomerular and postglomerular vasodilation. The lack of the presumed fall in FF may be the consequence of the expected DA1-induced renal vasodilation, partially reversed by the alpha adrenergic properties of ibopamine for this dose. Ibopamine caused no clinically significant natriuresis in these salt-depleted patients. No changes in PRA, aldosterone and catecholamines were found.",
keywords = "Dopamine, Heart failure (congestive), Ibopamine, Renal haemodynamics, Sodium excretion",
author = "Girbes, {A. R.J.} and Kalisvaart, {C. J.} and {Van Veldhuisen}, {D. J.} and Tan, {E. T.} and Smit, {A. J.} and Reitsma, {W. D.} and Pasteuning, {W. H.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1093/eurheartj/14.2.279",
language = "English",
volume = "14",
pages = "279--283",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "2",

}

Girbes, ARJ, Kalisvaart, CJ, Van Veldhuisen, DJ, Tan, ET, Smit, AJ, Reitsma, WD & Pasteuning, WH 1993, 'Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure' European Heart Journal, vol. 14, no. 2, pp. 279-283. https://doi.org/10.1093/eurheartj/14.2.279

Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure. / Girbes, A. R.J.; Kalisvaart, C. J.; Van Veldhuisen, D. J.; Tan, E. T.; Smit, A. J.; Reitsma, W. D.; Pasteuning, W. H.

In: European Heart Journal, Vol. 14, No. 2, 01.01.1993, p. 279-283.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure

AU - Girbes, A. R.J.

AU - Kalisvaart, C. J.

AU - Van Veldhuisen, D. J.

AU - Tan, E. T.

AU - Smit, A. J.

AU - Reitsma, W. D.

AU - Pasteuning, W. H.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - The effects of a single dose of ibopamine on renal haemodynamics, sodium excretion, blood pressure (BP) and heart rate (HR) were investigated in 10 patients (aged 52-82 years) with severe congestive heart failure (CHF) who were in NYHA class IV. All patients used ACE inhibitors, digoxin and diuretics. After determining baseline values, ibopamine 100 mg was administered.Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured simultaneously using radio pharmaceuticals. An increase in GFR and ERPF was observed during 3 and 2 h, with a maximum of 15 and 11%, respectively. The ratio GFR/ERPF representing the filtration fraction (FF) was markedly elevated at baseline, 34%, and remained unchanged. No clinically significant increase of sodium excretion was found. No changes in blood pressure, heart rate, plasma renin activity (PRA) and aldosterone or norepinephrine were observed. We conclude that ibopamine increases both ERPF and GFR in patients with severe CHF, possibly as a consequence of both inotropic cardiac and specific renal effects with equal preglomerular and postglomerular vasodilation. The lack of the presumed fall in FF may be the consequence of the expected DA1-induced renal vasodilation, partially reversed by the alpha adrenergic properties of ibopamine for this dose. Ibopamine caused no clinically significant natriuresis in these salt-depleted patients. No changes in PRA, aldosterone and catecholamines were found.

AB - The effects of a single dose of ibopamine on renal haemodynamics, sodium excretion, blood pressure (BP) and heart rate (HR) were investigated in 10 patients (aged 52-82 years) with severe congestive heart failure (CHF) who were in NYHA class IV. All patients used ACE inhibitors, digoxin and diuretics. After determining baseline values, ibopamine 100 mg was administered.Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured simultaneously using radio pharmaceuticals. An increase in GFR and ERPF was observed during 3 and 2 h, with a maximum of 15 and 11%, respectively. The ratio GFR/ERPF representing the filtration fraction (FF) was markedly elevated at baseline, 34%, and remained unchanged. No clinically significant increase of sodium excretion was found. No changes in blood pressure, heart rate, plasma renin activity (PRA) and aldosterone or norepinephrine were observed. We conclude that ibopamine increases both ERPF and GFR in patients with severe CHF, possibly as a consequence of both inotropic cardiac and specific renal effects with equal preglomerular and postglomerular vasodilation. The lack of the presumed fall in FF may be the consequence of the expected DA1-induced renal vasodilation, partially reversed by the alpha adrenergic properties of ibopamine for this dose. Ibopamine caused no clinically significant natriuresis in these salt-depleted patients. No changes in PRA, aldosterone and catecholamines were found.

KW - Dopamine

KW - Heart failure (congestive)

KW - Ibopamine

KW - Renal haemodynamics

KW - Sodium excretion

UR - http://www.scopus.com/inward/record.url?scp=0027523452&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/14.2.279

DO - 10.1093/eurheartj/14.2.279

M3 - Article

VL - 14

SP - 279

EP - 283

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 2

ER -